Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Mar 27, 2024 Form 3 Insider Report for Boundless Bio, Inc. (BOLD)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
BOLD
Transactions as of
Mar 27, 2024
Transactions value $
$0
Form type
3
Date filed
3/27/2024, 09:07 PM
Previous filing
Nov 21, 2022
Next filing
Apr 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BOLD Series B Preferred Stock Mar 27, 2024 Common Stock 190K Direct F1
holding BOLD Series C Preferred Stock Mar 27, 2024 Common Stock 366K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 19.5-for-1 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 Each share of Series C Preferred Stock is convertible into shares of Common Stock, on a 19.5-for-1 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.